Platinum Investment Management Ltd. Sells 87,278 Shares of ProQR Therapeutics N.V. $PRQR

Platinum Investment Management Ltd. lessened its holdings in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) by 5.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,450,969 shares of the biopharmaceutical company’s stock after selling 87,278 shares during the period. Platinum Investment Management Ltd. owned approximately 1.38% of ProQR Therapeutics worth $2,960,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Affinity Asset Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 16.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock valued at $4,368,000 after purchasing an additional 459,512 shares in the last quarter. Aberdeen Group plc bought a new position in ProQR Therapeutics in the first quarter valued at approximately $2,461,000. Walleye Capital LLC lifted its position in ProQR Therapeutics by 11.6% in the 1st quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company’s stock valued at $670,000 after acquiring an additional 52,261 shares in the last quarter. Monaco Asset Management SAM lifted its position in ProQR Therapeutics by 59.1% in the 1st quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company’s stock valued at $628,000 after acquiring an additional 175,290 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in ProQR Therapeutics by 512.8% in the 4th quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 320,614 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Up 1.4%

Shares of ProQR Therapeutics stock opened at $2.16 on Thursday. ProQR Therapeutics N.V. has a 12-month low of $1.07 and a 12-month high of $4.62. The stock has a market cap of $227.25 million, a P/E ratio of -4.70 and a beta of 0.23. The business’s 50 day moving average is $2.16 and its 200-day moving average is $1.87.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%.The company had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. On average, sell-side analysts expect that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.

Wall Street Analyst Weigh In

PRQR has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Evercore ISI restated an “outperform” rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Friday, June 27th. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $8.00.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).